A clinical trial of dexmedetomidine or remifentanil sedation for awake fibreoptic intubatio

Phase 3

• Conditions: Anaesthesia; Anaesthesiology - Anaesthetics

• Registration Number: ACTRN12605000231640
• Lead Sponsor: Dr Sarah Harper

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Awake fibreoptic intubation, no contraindication to remifentanil or dexmedetomidine.

Exclusion Criteria

Chronic alpha-2 agonist or opioid therapy, allergy or previous adverse reaction to study drugs, uncontrolled hypertension, heart <50, 2nd or 3rd degree heart block, severe ventricular, renal, hepatic or respiratory dysfuction, pregnancy or lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified